BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR Pharmaceutical Investing
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma Pharmaceutical Investing
Veklury® Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations Pharmaceutical Investing
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023 Pharmaceutical Investing
Boosh Plant-Based Brands Inc. Announces Engagement with Storied Health Partners and Debt Settlement Life Science Investing
CORRECTION FROM SOURCE: Correction of the Press Releases Dated January 9, 2023 and March 14, 2023 Life Science Investing
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year Pharmaceutical Investing
Gilead Sciences: 4 Questions: Global Experts Convene To Identify Key Measures to Long-Term Success in HIV Pharmaceutical Investing
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office Pharmaceutical Investing
Aptose to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference Market News
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation Pharmaceutical Investing
